Our key figures
Our revenue decreased by 7.4% (-4.8% organically). We delivered a profitability of a 20.0% adjusted EBITDA margin and free cash flow of CHF 27.1 million.
Share of revenue by business unit
2025
Share of revenue by business unit
2024
Key figures
millions of CHF | 2025 | % of revenue | +/–% change | 2024 | % of revenue | |||||
Revenue | 448.0 | 100.0% | –7.4% | 483.9 | 100.0% | |||||
Organic revenue growth 1) | –4.8% | |||||||||
Gross profit | 161.9 | 36.1% | 1.4% | 159.7 | 33.0% | |||||
Operating income (EBIT) | 22.8 | 5.1% | 76.7% | 12.9 | 2.7% | |||||
EBITDA | 78.3 | 17.5% | 5.1% | 74.5 | 15.4% | |||||
Adjusted EBITDA | 89.7 | 20.0% | –3.1% | 92.5 | 19.1% | |||||
Net income | 7.0 | 1.6% | n/a | –6.4 | –1.3% | |||||
Free cash flow (FCF) | 27.1 | –31.7% | 39.6 | |||||||
Operating net cash flow (ONCF) | 40.3 | –33.9% | 61.0 | |||||||
Capital expenditure, net (capex, net) | 41.7 | –5.9% | 44.3 | |||||||
Net debt as of December 31 | 216.5 | 5.4% | 205.3 | |||||||
Net debt adjusted EBITDA ratio as of December 31 | 2.41 | 8.7% | 2.22 | |||||||
Employees (number of full-time equivalents) as of December 31 | 2’574 | –4.1% | 2’684 |
1)Adjusted for currency effects.
Our KEY Figures
revenue in 2025
adjusted EBITDA margin
free cash flow generated in 2025
Stock market information
2025 | 2024 | |||
Registered share (in CHF) | ||||
– high | 13.50 | 18.68 | ||
– low | 8.34 | 8.28 | ||
– year-end | 11.24 | 8.80 | ||
Market capitalization as of December 31 | ||||
– number of shares issued | 41’262’370 | 41’262’370 | ||
– in millions of CHF | 463.8 | 363.1 | ||
– in percentage of equity | 109% | 83% | ||
P/E ratio as of December 31 | 71.8x | -48.7x | ||
Dividend yield as of December 31 | 0.9% | 5.7% |
Data per share
CHF | 2025 | 2024 | ||
Net income attributable to a shareholder of medmix Ltd | 0.16 | –0.18 | ||
Equity attributable to a shareholder of medmix Ltd | 10.30 | 10.60 | ||
Ordinary dividend | 0.101) | 0.50 | ||
Payout ratio | 64% | –277% | ||
Average number of shares outstanding as of December 31 | 40’773’826 | 40’779’842 |
1)Proposal to the Annual General Meeting.
Shareholder structure as of December 31, 2025
Number of shares | Number of shareholders | Shareholding | ||
1–100 | 2’246 | 0.3% | ||
101–1'000 | 3’308 | 3.4% | ||
1'001–10'000 | 1’111 | 7.6% | ||
10'001–100'000 | 122 | 7.8% | ||
More than 100'000 | 18 | 53.3% | ||
Total registered shareholders and shares (excluding treasury shares of medmix Ltd) | 6’805 | 72.3% |
Shareholder structure as of December 31, 2024
Number of shares | Number of shareholders | Shareholding | ||
1–100 | 2’485 | 0.3% | ||
101–1'000 | 3’585 | 3.6% | ||
1'001–10'000 | 1’019 | 7.0% | ||
10'001–100'000 | 102 | 6.7% | ||
More than 100'000 | 20 | 53.0% | ||
Total registered shareholders and shares (excluding treasury shares of medmix Ltd) | 7’211 | 70.6% |
Global reach, local presence
